Anthrax toxin is the major virulence factor produced by Bacillus anthracis. The toxin consists of three protein subunits: protective antigen (PA), lethal factor, and edema factor. Inhibition of PA binding to its receptors, tumor endothelium marker-8 (TEM8) and capillary morphogenesis protein-2 (CMG2) can effectively block anthrax intoxication, which is particularly valuable when the toxin has already been overproduced at the late stage of anthrax infection, thus rendering antibiotics ineffectual. Receptor-like agonists, such as the mammalian cell-expressed von Willebrand factor type A (vWA) domain of CMG2 (sCMG2), have demonstrated potency against the anthrax toxin. However, the soluble vWA domain of TEM8 (sTEM8) was ruled out as an anthrax toxin inhibitor candidate due to its inferior affinity to PA. In the present study, we report that L56A, a PA-binding-affinity-elevated mutant of sTEM8, could inhibit anthrax intoxication as effectively as sCMG2 in Fisher 344 rats. Additionally, pharmacokinetics showed that L56A and sTEM8 exhibit advantages over sCMG2 with better lung-targeting and longer plasma retention time, which may contribute to their enhanced protective ability in vivo. Our results suggest that receptor decoys based on TEM8 are promising anthrax toxin inhibitors and, together with the pharmacokinetic studies in this report, may contribute to the development of novel anthrax drugs.
Introduction
Anthrax toxin is the major virulence factor produced by Bacillus anthracis and consists of three protein subunits: protective antigen (PA), lethal factor (LF), and edema factor (EF). This toxin enters the cell cytoplasm and exerts toxic effects in a PA-mediated manner. More specifically, PA binds to cell surface receptors, forming a pre-pore complex after activation by furin at the cell membrane, followed by the binding of up to three molecules of LF and/or EF to the complex [1] . The entire complex is then internalized by receptor-mediated endocytosis [2] . Acidification in the endosome promotes transformation of the pre-pore complex into the pore complex and translocation of the catalytic LF and/or EF molecules into the cell cytosol.
The anthrax toxin receptors, tumor endothelium marker-8 (TEM8) [3] and capillary morphogenesis protein-2 (CMG2) [4] , are type one transmembrane proteins that contain an extracellular von Willebrand factor type A (vWA) domain , which has been well established as the domain that directly interacts with PA [3, 4] . Other parts of the extracellular and transmembrane regions are necessary for anthrax intoxication, but the cytoplasmic region does not seem to be required [5] . However, cytoplasmic tails could regulate the vWA domain's affinity for PA binding and are important for efficient toxin uptake [2, 6, 7] . The highly conserved MIDAS motif in the vWA domain has been shown to be the key site for metal ion-dependent interactions with PA D683 [8] . Although their vWA domains share 60% identical residues, the two receptors significantly differ in their binding to PA: the 153-154 site, residing in the b4-a4 loop of CMG2, presents an additional interaction with PA domain 2 that does not occur with TEM8 [9] .
Inhibition of PA binding to cell receptors has proven to be an effective therapy for anthrax intoxication. In addition to antibodies [10] and polyvalent molecules [11] targeted to the binding sites of PA or its receptors, soluble fragments of receptors, such as the mammalian cell-expressed vWA domain of CMG2 (sCMG2), have also been reported to inhibit PA-receptor binding [12] . Moreover, antibody Fc fragments have been fused to sCMG2, which efficiently improved their plasma residence time and preserved their affinity [13, 14] . Furthermore, the ability of sCMG2 to block antibody-resistant forms of anthrax toxin and relevant bacterial strains has been validated [13] . In addition, a new plant expression system has been built for producing Fc-fused CMG2 [14, 15] . However, because of its lower affinity, the vWA domain of TEM8 (sTEM8) was ruled out from the first antitoxin design [12] . Thus far, TEM8 in Fc fusion form has only been applied as an antitumor decoy [16] .
In our previous work, we found that the replacement of the L56 residue in sTEM8 with the homologous alanine residue found in sCMG2 (referenced as L56A) could improve the antitoxin efficacy of sTEM8 in a cell-based anthrax toxin neutralization assay [17] . In the current study, we confirm the elevated affinity of L56A to PA and demonstrate its potency as a toxin inhibitor in rats. Pharmacokinetic studies were performed to compare the behaviors of sTEM8, L56A, and sCMG2 in vivo. The results demonstrate the advantages of sTEM8-based constructs over sCMG2 as anthrax toxin inhibitors.
Results
sTEM8 and its mutant L56A exhibit lower PA binding affinities than sCMG2
In our previous work [17] , we demonstrated that the sTEM8 mutant L56A conferred increased protection to J774A.1 cells against anthrax lethal toxin (LeTx) challenge compared to wildtype sTEM8. To further evaluate the potency of L56A as an anthrax toxin inhibitor compared with sTEM8 and sCMG2 we prepared a new batch of proteins, repeated the cell protection assay and used an improved Schild plot analysis to compare the affinity of these constructs, as detailed in the experimental section.
All the constructs were soluble in the cytoplasm of Escherichia coli. Without moving the His tag, there would be additional residues (MSHHHHHHSM) at the N-termini of the recombinant proteins. For all the purified proteins, only a single band was shown at a lower molecular weight than expected on non-reducing polyacrylamide gels (Fig. 1A) , suggesting that the redundancy did not interfere with protein folding and the correct disulfide bond was formed, as the crystal structures showed [17] .
The protection assay yielded results consistent with our previous study [17] with IC 50 values of 274.668.7 nM, 69.565.8 nM, and 20.861.5 nM (Fig. 1B, Table 1 ) for sTEM8, L56A and sCMG2 respectively. sTEM8 and its more protective mutant L56A still performed less efficiently than sCMG2. Accordingly, the Schild plot analysis (Fig. 1C, Table 1 ) demonstrated that the sTEM8 mutant L56A elevated the affinity, with a Kd value 3.4 times lower than that of sTEM8, consistent with our previous results obtained by the BIAcore assays (29.8 nM for sTEM8 versus 4.44 nM for L56A) [17] . However, the affinity of L56A was still lower than that of sCMG2, with Kd values 11.1 times higher, confirming the results of the protection assay.
L56A exhibits similar or slightly better protection than sCMG2 in vivo Based on the ability of these receptor decoys to inhibit PA intoxication in vitro, we next tested the efficacy of sTEM8 and L56A compared to sCMG2 in vivo. Cell-produced sCMG2 has been reported to fully protect rats at a molar receptor: PA ratio of between 1:1 and 2:1, whereas cell-produced sTEM8 could not do so even at 15:1 [12] . In our studies, the bacterially-produced sCMG2 exhibited similar efficacy (Table 2) , conferring full protection at receptor: PA ratios of 3:1 and 1:1, and significantly increasing survival time at a ratio of 0.6:1 compared with the LeTx-only group. Meanwhile, the bacterially-produced sTEM8 exhibited toxin inhibition superior to that of the reported cellproduced sTEM8, conferring full protection at receptor: PA ratios of 10:1 and 5:1, and protecting three of the six rats at a ratio of 3:1 (Table 2) . This difference was consistent with the BIAcore results (the prokaryote-expressed form has Kd values about 4 times lower than the eukaryote-expressed form: 29.8 nM versus 130 nM [17, 18] , without considering the system errors). The difference between the two forms of sTEM8 may be ascribed to the different expression systems applied (with or without glycosylation, for example). As expected, the L56A mutant of sTEM8 performed better than sTEM8, conferring full protection at receptor: PA ratios of 3:1 and 1:1. Unexpectedly, however, L56A performed similarly to or slightly better than sCMG2 (with prolonged survival times of 115.369.660 min versus 91.6764.112 min, respectively, at receptor: PA ratios of 0.6:1. P = 0.0350, using the logrank test, GraphPad Prism software, San Diego California USA) (Fig. 2 , Table 2 ).
sTEM8 and L56A bind to plasma proteins with slower degradation rates than sCMG2 in vivo sTEM8 and L56A had unexpectedly high efficacies in vivo. This finding suggests that they may have pharmacokinetics that differs from sCMG2. To address this hypothesis, we radiolabeled sTEM8, L56A, and sCMG2 with Na 125 I. Gel filtration monitored by radiation was used to test the chromatographic behaviors of the 125 I-labeled proteins and the corresponding serum samples from rats after i.v. injection. The chromatography graphs are shown in Fig. 3 . The retention time of the scintillation peaks could be used to estimate the size of the proteins (or their metabolites) with labeled radioactivity. Generally, shorter retention times imply increased molecular size caused by plasma protein binding, while prolonged elution times imply degradation.
There were no significant differences between the behaviors of the standard samples ( 125 I-labeled proteins loaded directly). The three proteins all had single peaks with retention times slightly less than 10 min. After being injected i.v. into rats, sTEM8 and L56A exhibited comparable pharmacokinetics. The serum samples at 5 min showed only one peak, with a retention time of about 5 min. The clearly reduced retention times of the radiation peaks indicates that sTEM8 and L56A could bind to plasma proteins to form complexes with larger molecular weights. In contrast, a serum sample at 5 min showed a single peak for sCMG2 that was similar to that of its standard form, indicating a lack of plasma protein binding.
For the serum samples at 30 min, sTEM8 and L56A both showed two peaks: one with a retention time of about 5 min, similar to that of the serum samples at 5 min, likely representing the plasma protein binding complex, and another with a retention time of slightly more than 10 min, probably representing degraded metabolites. For sCMG2, only a single metabolite-peak with a prolonged retention time was observed. Comparing this with the chromatographic behaviors of the samples at 5 min suggests that sCMG2 degraded much faster than sTEM8 and L56A (Fig. 3) .
Pharmacokinetics of sTEM8, L56A, and sCMG2 indicate that all three proteins exhibit fast rates of elimination and extremely fast rates of distribution
The serum concentrations of 125 I-sTEM8, 125 I-L56A, and 125 I-sCMG2 after i.v. injection at a 62.5 mg/kg dose were monitored over time and are plotted in Fig. 4B . The serum concentration profiles were fitted to a two-compartment model (Fig. 4A) , and the related fitted curves are depicted in Fig. 4B with the corresponding pharmacokinetic parameters generated listed in Fig. 4C .
All three proteins exhibited fast elimination rates and much faster distribution rates, with an elimination half-life of less than 10 min and a distribution half-time of less than 1 min. For distribution, all three proteins were assigned higher values for K 12 than K 21 , indicating greater distribution in the second compartment. , Fig. 4C ), resulting in a slightly higher distribution ratio (0.56 versus 0.79, Fig. 4C ). The higher ratio for X c /X p implies that L56A and sCMG2 are more likely than sTEM8 to remain in pericompartments (such as target organs) but not central compart- The results for cell protection assays. Viability was assessed as described in the methods section. Each assay was performed at least three times, with duplicates within each assay. Data points represent the mean 6 SEM in duplicate for one representative experiment. C. The results for the Schild plot assays; a, b, and c. PA dose-dependent survival curves for cells at a fixed receptor/mutant concentration; d, e, and f. These graphs were obtained by plotting the EC 50 values corresponding to different receptor concentrations, fixed by linear regression using GraphPad Prism software. Each assay was performed at least three times. The data shown are for one representative experiment.
a Samples were not mixed with 2-mercaptoethanol. doi:10.1371/journal.pone.0020646.g001 ments (i.e., the circulation for body liquid), which may imply that their closer association with target organs contributes to their better performance.
For elimination, L56A exhibited the largest K del value, which was even larger than that of sCMG2. However, when associated with the larger distribution rate K 12 , its elimination half-life was averaged to approach that of sTEM8. sCMG2 exhibited an elimination rate about 2.5-fold higher than sTEM8 (32.07 h Tissue distributions show that sTEM8 and L56A target to the lungs, whereas sCMG2 targets to the kidney To compare the distribution of sTEM8, L56A, and sCMG2 in different tissues, TCA (Trichloroacetic Acid) sediments were investigated 5 min, 30 min, and 4 h after i.v. administration of a 67.5 mg/kg dose (Figs. 5) .
The results indicated that all three proteins had wide distributions in tissues throughout the entire body within the time course examined. Most of the tissues already had significantly enriched TCA-precipitable radiations by 5 min after administration, especially the lung, liver, kidney, and spleen. This showed maintenance of higher protein concentrations compared with the serum, indicating a fast distribution rate for all three of the proteins (Fig. 5 ).
sTEM8 and L56A presented similar organ-targeting for the lung, which exhibited the highest observed concentrations: 332%, 375%, and 129% of the injected dose (ID) for sTEM8 at 5 min, 30 min, and 4 h, respectively (Fig. 5A) , and 159%, 223%, and 19% for L56A (data sequenced) (Fig. 5B) . By comparison, the concentrations in serum were 143%, 67%, and 11% for sTEM8 and 47%, 20%, 6% for L56A (Figs. 5A & 5B) . When compared with other organs, the lung still received the largest fraction (presented as relative distribution in Figs. 5D & 5E); the concentration of sTEM8 in the lung accounted for 28%, 51%, and 49% of the sum of the concentrations of all the sampled tissues at 5 min, 30 min, and 4 h, respectively (Fig. 5D) , and 37%, 62%, and 17% for L56A (Fig. 5E ). By comparison, the relative distributions in the serum were 12%, 9%, and 4% for sTEM8 and 11%, 5%, and 6% for L56A (Figs. 5D & 5E) . At all the sampled time points, the lung exhibited much higher concentrations than the serum for both sTEM8 and L56A. For sCMG2, the concentration in the lung was comparable to that in the serum (Figs. 5C & 5F) at 5 min, and much less than was found in the lung for sTEM8 and L56A, in terms of both the absolute amount (%ID) and the relative distribution at 5 and 30 min.
By contrast, sCMG2 exhibited a completely different distribution, targeting the kidney rather the lung: %ID values for the kidney were 2310%, 235%, and 60% of the injected dose (Fig. 5C) , with relative distributions of 80%, 44%, and 19% at 5 min, 30 min, and 4 h, respectively. By comparison, %ID values for serum were 57%, 10%, and 4%, with relative distributions of 2%, 2%, and 1.2% (Fig. 5C ). sTEM8 and L56A did not show any significant pooling in the kidney compared with the serum (Figs. 5A , 5B, 5D, & 5E), and the concentrations and relative distributions were much lower than for sCMG2 at all time points. 
Discussion
The comparable in vivo performance of L56A compared with sCMG2 is unexpected, considering its clearly lower potency observed in the in vitro assays (directly shown as IC 50 , 69.565.8 nM versus 20.861.5 nM), which was comparatively consistent with the apparent affinity detected (displayed as 1/slope, 31.74 versus 3.78, Table 1 ). Moreover, considering that the results of groups sTEM8/LeTX 3:1 and L56A/LeTx 0.6:1 did not show significant differences (p = 0.1514, logrank test, Fig. 2, Table 2 ), the relative in vivo performance of L56A versus sTEM8 was comparable to that in vitro (274.6 nM versus 69.5 nM, Table 1 ). The discrepancy between the in vitro and in vivo efficacy of the sTEM8-based decoys (sTEM8 and its mutant form L56A) and sCMG2 imply that inconsistencies occur after i.v. administration.
The size exclusion HPLC-flow scintillation analysis showed that sTEM8 and L56A exhibited an ability to bind plasma proteins, whereas sCMG2 did not. The analysis also indicated that sCMG2 may disrupt faster in plasma. The greater than 90% plasma protein binding for sTEM8 and L56A may be ascribed to their negative charge, which is predicted to be about 26.10 at pH 7.0 and is supported by the chromatography strategy used, as implied by the research on oligonucleotide pharmacokinetics [19] . By comparison, sCMG2 carries a positive charge of about 1.37 and did not bind to anion-exchange columns at near-neutral pH. However, measurements of the dependence of plasma binding on pH and ion strength are still needed to test this nonspecific binding hypothesis, although specific receptor-ligand interactions in the plasma seem unlikely [16, 20] .
Tissue distribution studies showed that sTEM8 and L56A mainly target to the lung, whereas sCMG2 targets to the kidney but not the lung. sTEM8 and L56A contain a lung-targeting GFE motif, whereas sCMG2 contains a kidney-targeting DRG motif [21, 22] , which may partially explain their differential targeting. However, multiple factors may contribute to organ specific distribution. For constructs with molecular weights of about 21 Kd, glomerular filtration in the kidney may be the main pathway of elimination. Plasma-binding may help sTEM8 and L56A escape this process to some extent. Certain receptor-ligand interactions may also contribute to the distribution of sTEM8 and its variant L56A. TEM8 is expressed in the respiratory epithelium of the bronchi, especially in the ciliated epithelial cells surrounding the luminal surface, the smooth muscle cells surrounding the vessels, and the epithelial cells lining the alveoli but is only weakly expressed in the endothelial cells lining the pulmonary vessels, as determined by immuno-histochemistry in mice using an anti-TEM8 polyclonal antibody that specifically recognizes the longform of TEM8 localized at the cell surface [23] . Immunohistochemical studies have also shown the expression of CMG2 in the epithelial cells lining the skin, colon, and lung and in the vascular endothelium of these tissues in mice [24, 25] . Further studies have used real-time RT-PCR to show that both TEM8 and CMG2 are expressed in the lung, with TEM8 being more highly-expressed, but neither are expressed in the kidney [26] . Considering their homology, TEM8 and CMG2 may also be expressed as cell receptors in the lungs of rats. The concurrence between the target organ and the organ-specific expression may imply that organtargeting may be receptor-ligand interaction dependent. This assumes that the physical ligand would always be present near its receptors. In the pharmacokinetic study, this receptor-ligand interaction may result in some non-linear characteristics, which may require further examination. The physiological functions of TEM8 and CMG2 remain unclear. However, the vWA domain of CMG2 has been reported to bind to basement-membrane Table 2 . doi:10.1371/journal.pone.0020646.g002 matrix proteins, collagen type IV, and laminin [20] , whereas TEM8 binds to collagen I and gelatin [27] . These matrix proteins are potential binding targets considering the reported colocalization of CMG2 and collagen type IV [24] . However, they cannot explain organ-specific pooling because they are distributed extensively throughout the body. sCMG2 appeared to be incapable of lung-targeting, given that the spleen was the second organ target and the lung did not show any enrichment compared to other organs (Fig. 5) . Given the conclusive evidence that TEM8 and CMG2 are expressed as cell surface receptors in the lungs of mice [23, 24] , the targeting of sTEM8 and L56A to the lung may account for their superiority in protecting the lung from anthrax toxin attack.
The pharmacokinetic parameters based on the drug concentration-time curve showed that all three proteins distributed and were eliminated at a fast rate. The fast distribution rate constant a for L56A is in accordance with its elevated affinity over sTEM8, which supports the involvement of receptor-ligand interactions as a mechanism contributing to their tissue distribution, given that they share the same targeting motif and have only a single difference at residue 56, which is distant from the GFE motif. In this way, this hypothetical ligand may interact with the ATRs in much the same way as PA does. Moreover, with a much higher affinity, the value of a for sCMG2 is less than that for L56A, implying that sCMG2 exhibits a different mechanism for distribution or employs a different receptor-ligand interaction that is much more difficult to assess or has weaker binding. With regard to elimination, sTEM8 and L56A presented longer half-lives than did sCMG2, which may be ascribed to the plasma protein binding that protects the constructs from protease-mediated catalysis, and also to their tissue azAb AzB , K del~a b K 21 and K 12~a zb{K 21 {K del . K 21 , and K 12 represents the crossing rate between compartments, and K del represents the excretion rate out of the system, as symbolized in figure 4A . X C /X P represents the ratio of drug amount distributed in the central compartment to that of the peri-compartment at equilibrium, which equaled K 21 /K 12 . doi:10.1371/journal.pone.0020646.g004
distribution to lung, which may function as a reservoir, instead of the kidney, which may facilitate clearance from the body. Overall, plasma protein binding and lung targeting seem to confer superior efficacy to sTEM8 and L56A over sCMG2 in vivo, which may explain why their performance approached that of sCMG2 after i.v. administration, despite their inferior protection in vitro.
The superiority of receptor-like decoys over antibody-based antitoxins lies in their ability to accurately mimic the natural receptor independent of natural or artificial changes in the toxin's amino acids, which would easily incapacitate the ability of sitespecific antibodies to block toxicity [14] . This characteristic indicates that decoy design strategies should emphasize competition with the physical receptor, with equal consideration placed on elevating affinity and improving target organ access. It has been reported that PA, together with LF and EF, are all rapidly degraded, with early localization of radioactivity in the liver, spleen, and intestines and excretion through the kidneys [28] .
However, for anthrax, present evidence indicates that the lung, rather than the liver, is the organ that both expresses the relevant toxin receptors and is the chief focus of infection and pathogenesis [26, 29] . It is possible that PA that distributes to target organs at a dose under the level of detection may still be sufficient for intoxication, which may emphasize the importance of colocalizing decoys with the corresponding native receptors to block the receptors and not just the toxin in circulation. sTEM8 and its higher-affinity variant L56A, which is designed by homology exchange to preserve the natural receptor's character, could effectively target the lung and confer protection to rats with a performance approaching or even exceeding that of sCMG2. This is extremely unexpected given their relatively lower affinities for PA. However, their plasma residence times were still too short for drug applications. Given that Fc-fusion strategies have been applied to sCMG2, which effectively prolongs its half time while preserving its decoy function, similar strategies may be explored to develop prospective decoys based on sTEM8 or L56A with elevated affinities, prolonged plasma residence times and improved organ targeting in anthrax antitoxin research.
Materials and Methods
Plasmid construction, protein expression and purification DNA fragments of the vWA domains of TEM8 (aa 38-220, GenBank Accession Number AF421380; denoted as sTEM8) and CMG2 (aa 38-218, GenBank Accession Number AY233452; denoted as sCMG2) were amplified from cDNAs maintained in our laboratory and cloned into PHAT vectors (EMBL, Heidelberg) between NcoI and BamHI sites with a six-His tag at the 59 end. Mutant L56A was obtained by inverse polymerase chain reaction (PCR) using mutation-inducing primers at the base of sTEM8 [17] . All clones were then validated by sequencing. In all constructs, the Cys-Ala mutation (Cys 177 in TEM8 and Cys 175 in CMG2) was introduced to reduce dimer formation during protein expression.
The constructs were expressed in BL21 (DE3) strains. After growth for 4 h in 1 l of LB medium, the cell cultures were induced with 0.4 mM IPTG for 16 h at 16uC. After ultrasonication, the supernatants were separated using a Ni-affinity column (GE Healthcare). sTEM8 and L56A were changed into Tris buffer (pH 8.0) with 50 mM sodium chloride by ultrafiltration, after which the target peaks were polished using a Source30Q column (GE Healthcare). sCMG2 was changed into Tris buffer (pH 9.0) containing 50 mM sodium chloride, and the peaks were directly collected after being passed through a Source30Q column. Finally, all proteins were concentrated and changed into Tris buffer (pH 8.0) with 150 mM sodium chloride. The purity of the recombinant proteins was analyzed by SDS-PAGE followed by Coomassie Brilliant Blue staining. The protein concentrations were then determined by the BCA Protein Assay (Thermo Scientific, Rockford).
Cell protection assay and Schild plot analysis
Mouse macrophage J774A.1 cells were plated at 30,000 cells/ well in 96-well plates and cultured for 24 h before treatment. The cells were then pre-cooled to 4uC to stop endocytosis. For the cell protection assay, a dilution series of the constructs, combined with PA and LF (final concentration of 100 ng/ml each), was added to the cells to a final volume of 100 ml/well. For the Schild plot analysis, a dilution series of PA combined with LF (final concentration of 100 ng/ml) was added to the cells along with different concentrations of the constructs. Next, the plates were incubated at 4uC for 2 h for complete competition and then transferred to 37uC. Cell viability was assayed 4 h after treatment by replacing the medium with 100 ml of fresh medium (MEM plus 2% FBS) containing 1 mg/ml MTT (Invitrogen, USA). After 1 h of incubation at 37uC, the medium was removed and the blue pigment produced by the viable cells was dissolved in 50 ml/well of 0.5% (w/v) SDS and 25 mM hydrochloric acid in 90% (v/v) isopropanol. The plates were then vortexed, and oxidized MTT was measured as the absorbance at 570 nm using a Model 550 microplate reader (Bio-Rad, USA). Cell viability was calculated as a percentage using the equation (OD mesured 2OD death control )/ (OD live control 2OD death control ), where ''live control'' wells contain LF alone and ''death control'' wells contain both 100 ng/ml PA and 100 ng/ml LF. IC 50 or EC 50 values were determined by nonlinear regression sigmoidal dose-response analysis with variable slopes (Prism, version 4.0; GraphPad, USA). Each assay was performed at least three times, with duplicates within each assay. The model used to fit the probable mathematical relationship between affinity and inhibition concentration is detailed in Supporting Information S1.
Anthrax lethal toxin (LeTx) challenge in rats
In vivo experiments with animals were performed according to previously published methods [30] . All experiments were approved by the Animal Care and Use Committee of the Beijing Institute of Microbiology and Epidemiology (permit numbers: 20100701 and 20101101). Male Fisher 344 rats (Vital River, China) weighing 200-250 g were challenged with LeTx (50 mg PA mixed with 25 mg LF to a final volume of 500 ml in PBS per rat) via the tail vein. For rats that received receptors or mutants, decoys were also added to LeTx to a final volume of 500 ml, and the resultant solution was co-injected into the rats. The rats were then monitored for intoxication symptoms and death. Statistical analysis was conducted using the logrank test (Prism, version 4.0). [31] . sTEM8, L56A, and sCMG2 were radiolabeled with Na 125 I using the Iodo-Gen method as described in the manual. Briefly, 1 ml of each protein (2 mg/ml) was incubated with 50 ml of Na 125 I (5 mCi) in a reaction tube coated with 100 mg of iodogen at room temperature with gentle stirring for 10 min. The incubation was stopped by the addition of PBS (20 mM, pH 7.4). After incubation, to separate free 125 I from the protein-bound 125 I, the iodinated protein was purified on a Sephacyl TM S-200 highresolution column (1 cm640 cm) by eluting with PBS (20 mM, pH 7.4) at a flow rate of 1 ml/min. The effluents were collected at 1-min intervals. Through radioactivity determination, the fractions containing 125 I-labeled protein were collected, and the remaining fractions were discarded. Under size exclusion chromatography conditions, 125 I-sTEM8, 125 I-L56A, and 125 I-sCMG2 were all eluted between 9 to 12 min, whereas free 125 I was eluted between 16 to 18 min after injection. The radiochemical purity of the 125 Ilabeled protein was confirmed to be greater than 95% as determined by HPLC. The proteins labeled with 125 I had a specific activity of 198.19 kBq/mg for sTEM8, 141.23 kBq/mg for L56A and 56.67 kBq/mg for sCMG2.
Radio iodination and purification
Validation of radioactivity determination in serum, urine, and tissues by TCA precipitation assay Precipitation of the iodinated proteins in the plasma and tissues by ice-cold 10% TCA was used to remove free 125 I or 125 I associated with the fragmented peptides. Hence, TCA-precipitable radioactivity rather than total radioactivity was used to calculate the 125 I-protein concentration in rat serum and tissue homogenate samples. A series of calibration standards were prepared by adding five concentrations of 0.045-11.528 mg/ml for 125 I-L56A, 0.054-33.7 mg/ml for sTEM8, and 0.03-16.08 mg/ml for sCMG2 into the blank serum, tissue and urine samples that were examined. The relationship between the added concentrations and measured radioactivity of the standards was evaluated. The results showed good relationships (r 2 .0.99) and recovery (.80%) for the entire matrix.
Pharmacokinetic studies
Rats (n = 6, 200620 g) were i.v. injected with 125 I-L56A, 125 IsTEM8, and 125 I-sCMG2 at a dose of 67.5 g/kg via the tail vein (at volume 250 ml). Blood samples (approximately 200 ml each) were collected from the tail vein at 0, 5, 10, 20 min, and 0.5, 1, 2, and 4 h from the same rat and then centrifuged at 3000 g for 10 min. Serum samples at 5 min, 30 min, and 4 h after dosing were analyzed by size exclusion HPLC (TSK G3000 SWXL gel column, 300 Å , 10 mm, 7.8 mm6300 mm)-flow scintillation analyzer (Radiomatic Model 600TRSeries, PerkinElmer, USA) to investigate the metabolism of each protein in vivo. 125 I-protein-associated radioactivity in the serum samples was determined after precipitation with TCA (10%, v/v). Briefly, each serum aliquot (50 ml) was added to 0.4 ml of ice-cold TCA (10%, v/v), vortex-mixed, and incubated on ice for 30 min. The mixture was then centrifuged at 16,0006g at 4uC for 10 min, and the supernatant, containing free 125 I or 125 I associated with fragmented peptide, was aspirated from each sample. The resultant TCA precipitate was then counted using a gamma counter (2470-005, WIZARDTM PerkinElmer, Finland) to determine the amount of 125 I radioactivity that remained associated with precipitable protein. Three groups of rats (n = 6 per group) were i.v. injected at a single dose of 67.5 g/kg in the same manner as described above.
The rats in the three groups were sacrificed by decapitation at 5 min, 0.5, and 4 h post-dosing, and blood and urine samples (300-400 ml) were immediately collected. Blood aliquots were immediately processed, and the resultant serum samples were analyzed as described. The tissues or organs including the heart, lung, liver, spleen, kidney, bladder, testis, jejunum, adipose, muscle and brain were excised, trimmed of extraneous fat, residual muscle and connective tissue, thoroughly rinsed of residual blood or contents with ice-cold 20 mM PBS (pH 7.4), and blotted dry. For radioactivity assays, small slices of tissues/organs were individually weighed, recorded and immediately homogenized twice at 8000 rpm for 30 s each time in 400 ml of ice-cold TCA (10%, v/v). The homogenates were then centrifuged at 3000 rpm for 10 min at 4uC, and the pellet was used for counting in the gamma counter.
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